The glucagon-like peptide 1 (GLP-1) agonist tirzepatide lowers the risk for cardiovascular (CV) events in patients with obesity and heart failure with preserved ejection fraction (HFpEF), whether they have general adiposity, measured with the body mass index (BMI), or central adiposity, measured with the waist-to-height ratio, showed a new analysis from the SUMMIT trial.
This is important because central adiposity, relative to general obesity, appears to be so critical to CV risk in patients with HFpEF that some experts are now calling for BMI to be completely replaced by waist-to-height ratio in patient assessments, according to Barry A. Borlaug, MD, a consultant in the Division of Interventional Cardiology at the Mayo Clinic in Rochester, Minnesota.
With the growing epidemic of heart failure, particularly HFpEF,…